Synairgen (SNG) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Mar 2020 04:48 PM
RNS
Second Price Monitoring Extn
20 Mar 2020 04:40 PM
RNS
Price Monitoring Extension
20 Mar 2020 02:00 PM
RNS
Price Monitoring Extension
19 Mar 2020 02:06 PM
RNS
Second Price Monitoring Extn
19 Mar 2020 02:01 PM
RNS
Price Monitoring Extension
19 Mar 2020 09:05 AM
RNS
Second Price Monitoring Extn
19 Mar 2020 09:00 AM
RNS
Price Monitoring Extension
18 Mar 2020 07:00 AM
RNS
Synairgen to start trial of SNG001 in COVID-19
10 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
17 Oct 2019 03:53 PM
RNS
Holdings in Company
16 Oct 2019 07:30 AM
RNS
Holding(s) in Company
30 Sep 2019 07:00 AM
RNS
Half-year Report
27 Sep 2019 07:00 AM
RNS
Phase II Biomarker Data for SNG001 to be presented
24 Jul 2019 07:00 AM
RNS
Phase II Clinical Trial Update
08 Jul 2019 05:48 PM
RNS
Holdings in Company
03 Jun 2019 11:52 AM
RNS
Result of AGM
18 Apr 2019 09:20 AM
RNS
Directorate Change, Annual Report & Notice of AGM
05 Apr 2019 12:55 PM
RNS
Grant of Options
14 Mar 2019 07:00 AM
RNS
Positive DSMC Review of Phase II Study for SNG001
25 Feb 2019 07:00 AM
RNS
Preliminary results for the year ended 31 Dec 2018
17 Jan 2019 08:31 AM
RNS
Update on LOXL2 programme with Pharmaxis
22 Oct 2018 10:05 AM
RNS
Holding(s) in Company
22 Oct 2018 07:00 AM
RNS
Part 2 start of Phase II COPD trial
16 Oct 2018 03:01 PM
RNS
Holding(s) in Company
15 Oct 2018 08:49 AM
RNS
Holding(s) in Company
12 Oct 2018 11:05 AM
RNS
Result of General Meeting
12 Oct 2018 10:29 AM
RNS
Result of General Meeting
25 Sep 2018 05:56 PM
RNS
Result of Fundraise
25 Sep 2018 01:01 PM
RNS
Proposed Fundraise to raise c.£2.9 million
25 Sep 2018 01:00 PM
RNS
Half-year Report
28 Jun 2018 07:00 AM
RNS
Positive SNG001 Biomarker Data in COPD Patients
26 Jun 2018 01:05 PM
RNS
Holding(s) in Company
22 Jun 2018 11:42 AM
RNS
Result of AGM
22 Jun 2018 07:00 AM
RNS
Synairgen Safety Data with SNG001 in COPD Patients
17 May 2018 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
16 Apr 2018 04:29 PM
RNS
Holding(s) in Company
06 Apr 2018 12:14 PM
RNS
Grant of Options
03 Apr 2018 05:21 PM
RNS
Holding(s) in Company
15 Mar 2018 03:13 PM
RNS
Issue of Equity
15 Mar 2018 03:11 PM
RNS
Holding(s) in Company
15 Mar 2018 07:00 AM
RNS
Preliminary results for year ended 31 Dec 2017
07 Feb 2018 07:00 AM
RNS
Synairgen starts dosing in Phase II COPD study
14 Dec 2017 07:00 AM
RNS
Update on LOXL2 Programme&Pharmaxis Collaboration
08 Nov 2017 04:31 PM
RNS
Holding(s) in Company
27 Sep 2017 07:00 AM
RNS
Data update and clinical plan for COPD
27 Sep 2017 07:00 AM
RNS
Interim results for six months ended 30 June 2017
13 Sep 2017 12:44 PM
RNS
Holding(s) in Company
06 Sep 2017 07:00 AM
RNS
LOXL2 Inhibitor Update.
28 Jun 2017 12:41 PM
RNS
Result of AGM
05 Jun 2017 07:00 AM
RNS
Posting of Annual Report and Notice of AGM

Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic.

Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections.

Synairgen share price launched at 155p in 2004.

UK 100

Latest directors dealings